🔬 What’s Shaping the Future of MDD Treatment Searches Across Europe?
Dive into the latest data-driven insights from LucidTrends as we explore how search interest for key treatments in Major Depressive Disorder (MDD) has evolved across the EU4 (France, Germany, Italy, and Spain) between 2022 and 2024.
From the enduring dominance of SEROQUEL to the rising momentum of ABILIFY and BRINTELLIX, this snapshot unpacks the dynamic shifts in awareness, regional patterns, and patient curiosity. Plus, discover the unique positioning of SPRAVATO and why Lithium remains under the radar.
🌍 Key Takeaways:
• ABILIFY and BRINTELLIX are gaining traction—what’s driving their growth?
• SEROQUEL remains dominant but shows a slow decline in interest
• SPRAVATO sees fluctuating interest—what might be holding it back?
• Regional search patterns reveal surprising insights across France, Spain, Germany, and Italy
• Related drug searches suggest evolving co-prescription and comparison trends
• Strategic takeaways for pharma marketers, medical affairs, and clinical teams
💡 Whether you’re a healthcare strategist, MSL, or neuromarketing analyst, this breakdown is packed with actionable intelligence from real-world digital behavior.
📩 Want to dive deeper into the insights?
➡️ Grab a copy of the full report: https://bit.ly/41Whd2n
➡️ Visit www.lucidtrends.io to find out more about LucidTrends.
#Neuroscience #MDD #MentalHealthTrends #DigitalHealth #LucidTrends #DepressionTreatment #PharmaInsights #EU4 #HealthcareMarketing #SPRAVATO #ABILIFY #BRINTELLIX #SEROQUEL #Lithium #LucidQuest #PsychiatryInsights #ClinicalStrategy